{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T14:29:45Z","timestamp":1768314585741,"version":"3.49.0"},"reference-count":3,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2016,10,17]],"date-time":"2016-10-17T00:00:00Z","timestamp":1476662400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2017,1]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>Advanced therapy medicinal products (<jats:styled-content style=\"fixed-case\">ATMP<\/jats:styled-content>s) represent the current pinnacle of \u2018patient\u2010specific medicines\u2019 and will change the nature of medicine in the near future. They fall into three categories; somatic cell\u2010therapy products, gene therapy products and cells or tissues for regenerative medicine, which are termed \u2018tissue engineered\u2019 products. The term also incorporates \u2018combination products\u2019 where a human cell or tissue is combined with a medical device. Plainly, many of these new medicines share similarities with conventional haematological stem cell transplant products and donor lymphocyte infusions as well as solid organ grafts and yet <jats:styled-content style=\"fixed-case\">ATMP<\/jats:styled-content>s are regulated as medicines and their development has remained predominantly in academic settings and within specialist centres. However, with the advent of commercialisation of dendritic cell vaccines, chimeric antigen receptor (<jats:styled-content style=\"fixed-case\">CAR<\/jats:styled-content>)\u2010T cells and genetically modified autologous haematopoietic stem cells to cure single gene\u2010defects in \u03b2\u2010thalassaemia and haemophilia, the widespread availability of these therapies needs to be accommodated. Uniquely to <jats:styled-content style=\"fixed-case\">ATMP<\/jats:styled-content>s, the patient or an allogeneic donor is regularly part of the manufacturing process. All of the examples given above require procurement of blood, bone marrow or an apheresate from a patient as a starting material for manufacture. This can only occur in a clinical facility licensed for the procurement of human cells for therapeutic use and this is likely to fall to haematology departments, either as stem cell transplant programmes or as blood transfusion departments, to provide under a contract with the company that will manufacture and supply the final medicine. The resource implications associated with this can impact on all haematology departments, not just stem cell transplant units, and should not be under\u2010estimated.<\/jats:p>","DOI":"10.1111\/bjh.14384","type":"journal-article","created":{"date-parts":[[2016,10,17]],"date-time":"2016-10-17T10:29:03Z","timestamp":1476700143000},"page":"9-15","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["The expanding role of the clinical haematologist in the new world of advanced therapy medicinal products"],"prefix":"10.1111","volume":"176","author":[{"given":"Mark W.","family":"Lowdell","sequence":"first","affiliation":[{"name":"Royal Free London NHS Foundation Trust &amp; University College London London UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amy","family":"Thomas","sequence":"additional","affiliation":[{"name":"Human Tissue Authority London UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2016,10,17]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2014.271"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)60737-5"},{"key":"e_1_2_11_4_1","unstructured":"RMEG(2014)Building on our own potential: a UK pathway for regenerative medicine. A report from the Regenerative Medicine Expert Group.https:\/\/www.gov.uk\/government\/uploads\/system\/uploads\/attachment_data\/file\/415919\/build-on-potential.pdf"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbjh.14384","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbjh.14384","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.14384","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,2]],"date-time":"2023-10-02T13:21:19Z","timestamp":1696252879000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/bjh.14384"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10,17]]},"references-count":3,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,1]]}},"alternative-id":["10.1111\/bjh.14384"],"URL":"https:\/\/doi.org\/10.1111\/bjh.14384","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,10,17]]},"assertion":[{"value":"2016-10-17","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}